Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14438399 | 0.87 | RPS6KB1 (0.46) | RPS6KB1AKT1AURKBINCENPSLC6A2 | |
| SCHEMBL14438353 | 0.87 | RPS6KB1 (0.46) | RPS6KB1AKT1AURKBINCENPSLC6A2 | |
| SCHEMBL16419143 | 0.84 | HRH3 (0.45) | OPRK1 | |
| SCHEMBL18211049 | 0.84 | HRH3 (0.45) | OPRK1 | |
| SCHEMBL9510114 | 0.82 | SMN1; SMN2 (0.38) | RPS6KB1AKT1AURKBINCENPOPRK1 | |
| SCHEMBL9457954 | 0.82 | OPRK1 (0.46) | RPS6KB1AKT1AURKBINCENPOPRK1 | |
| SCHEMBL28163310 | 0.82 | SMN1; SMN2 (0.45) | — | |
| SCHEMBL2947193 | 0.82 | SMN1; SMN2 (0.45) | — | |
| SCHEMBL9511233 | 0.82 | SMN1; SMN2 (0.38) | RPS6KB1AKT1AURKBINCENPOPRK1 | |
| SCHEMBL28163316 | 0.82 | RPS6KB1 (0.49) | RPS6KB1AKT1AURKBINCENPSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197522-A1 | Dpp-iv inhibitors | DPP7, DPP4, DPP3 | RPS6KB1 3581/4885AKT1 3640/4885AURKB 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.